Lifecodes to Develop HLA Applications on Luminex Technology

- Lifecodes to Market Reagents and Instrumentation

Using LabMAP(TM) Technology -



Apr 26, 2001, 01:00 ET from Luminex Corporation and Lifecodes Corporation

    AUSTIN, Texas and STAMFORD, Conn., April 26 /PRNewswire/ --
 Luminex Corporation (Nasdaq:   LMNX) and Lifecodes Corporation announced today
 that they have entered into a multi-year strategic partnership permitting
 Lifecodes to develop various HLA based applications for use on Luminex
 technology.  Lifecodes will market reagents and Luminex's LabMAP
 instrumentation under its LIFEMATCH(TM) brand.  Lifecodes's product offerings
 will range from catalog and custom products to technology licensing, research
 services, large-scale production and life science technical expertise and
 support.
     Under the terms of the agreement, Lifecodes has been granted worldwide
 nonexclusive rights to develop and distribute reagents and Luminex's LabMAP
 instrumentation under its LIFEMATCH(TM) brand.  For these rights, Luminex will
 receive royalties from the commercialization of Lifecodes' products based on
 Luminex's technology.  Lifecodes will focus on developing kits based on the
 multi-analyte profiling capabilities of the Luminex technology.  Lifecodes
 will also market Luminex instrumentation to its customers.
     "We are very excited about our partnership with Luminex and the potential
 of the LabMAP system," stated Robert Linke, Director of Products for
 Lifecodes.  "This technology allows us to develop multiplex HLA DNA assays and
 antibody detection assays for use on a single automated platform.  Previously,
 these two tests were performed with different methodologies and on different
 platforms.  We can now offer the lab a system which can generate savings in
 consumables, labor and time."
     In early May 2001, Lifecodes will make available the first in a series of
 multiplex assays (branded LIFEMATCH(TM)) for HLA DNA typing and antibody
 screening.  Six more assays are planned for release over the next 6 to
 12 months.
     Luminex's LabMAP technology is a proprietary biological testing platform
 that can perform up to 100 assays simultaneously on a single drop of fluid
 with the capability for medium to high throughput assay applications.  This
 system combines the use of low-cost microsphere-based assays with small
 lasers, advanced digital signal processors and proprietary software to offer
 greater speed, precision and flexibility over current bioassay technologies.
     "We are very excited to announce the addition of Lifecodes to our growing
 list of strategic partnerships," stated John Porter, Luminex's Director of
 Business Development.  "Lifecodes is a leading provider of DNA testing
 services and related products for genetic typing of potential donors and
 recipients for transplants, and we are pleased that they are using our
 technology to expand their product lines."
 
     About Lifecodes Corporation
     Lifecodes, headquartered in Stamford, Connecticut, is one of the largest
 providers of molecular products and services for HLA, paternity and forensics.
 The company is a leader in the development, manufacture and distribution of
 molecular HLA typing products used by major bone marrow registries worldwide.
 Lifecodes also owns and operates six testing laboratories, four in the U.S.,
 and one each in Canada and Germany that provide forensic, paternity and HLA
 testing services.  The company offers the most expansive network of identity
 testing labs in North America.  For additional information regarding Lifecodes
 Corp., please contact: Lifecodes Corp. at 550 West Ave., Stamford, CT 06902,
 Phone: 1-800-LIFECODES (543-3263), Fax: 203-328-9599 or Internet:
 www.Lifecodes.com.
 
     About Luminex Corporation
     Luminex Corporation develops, manufactures and markets proprietary
 biological testing technologies with applications throughout the life sciences
 industry.  The company's LabMAP(TM) system is an open-architecture, multi-
 analyte technology platform that delivers fast, accurate and cost-effective
 bioassay results to markets as diverse as pharmaceutical drug discovery,
 clinical diagnostics and biomedical research, including the genomics and
 proteomics research markets.  The company's LabMAP(TM) technology is sold
 worldwide and is already in use in leading research laboratories as well as
 major pharmaceutical, diagnostic and biotechnology companies.  Further
 information on Luminex Corporation or LabMAP(TM) can be obtained on the
 Internet at http://www.luminexcorp.com.
 
     Statements made in this press release that express Luminex's or
 management's intentions, plans, beliefs, expectations or predictions of future
 events are forward-looking statements.  The words "believe," "expect,"
 "intend," "estimate," "anticipate," "will" and similar expressions are
 intended to further identify such forward-looking statements.  It is important
 to note that the company's actual results or performance could differ
 materially from those anticipated or projected in such forward-looking
 statements.  Factors that could cause Luminex's actual results or performance
 to differ materially include risks and uncertainties relating to market demand
 and acceptance of Luminex's products, the company's dependence on strategic
 partners for development and distribution of products, competition, Luminex's
 ability to scale-up manufacturing operations, potential shortages of
 components and the timing of regulatory approvals, as well as the risks
 discussed under the heading "Factors That May Affect Future Results" in
 Luminex's annual report on Form 10-K for the year ended December 31, 2000, as
 filed with the Securities and Exchange Commission.  The forward-looking
 statements contained herein represent the judgment of Luminex as of the date
 of this press release, and Luminex expressly disclaims any intent, obligation
 or undertaking to update or revise such forward-looking statements to reflect
 any change in Luminex's expectations with regard thereto or any change in
 events, conditions or circumstances on which any such statements are based.
 
     Editor's Note:
     Information on Luminex and LabMAP(TM) can be found on the Internet at
 http://www.luminexcorp.com.
     Information on Lifecodes can be found on the Internet at
 http://www.lifecodes.com
 
      Contacts:
      Lifecodes Corporation                   Luminex Corporation
      (203) 328-9533                          (512) 219-8020
      Robert Linke                            John M. Porter
      Director, Products                      Director of Business Development
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X75136655
 
 

SOURCE Luminex Corporation and Lifecodes Corporation
    AUSTIN, Texas and STAMFORD, Conn., April 26 /PRNewswire/ --
 Luminex Corporation (Nasdaq:   LMNX) and Lifecodes Corporation announced today
 that they have entered into a multi-year strategic partnership permitting
 Lifecodes to develop various HLA based applications for use on Luminex
 technology.  Lifecodes will market reagents and Luminex's LabMAP
 instrumentation under its LIFEMATCH(TM) brand.  Lifecodes's product offerings
 will range from catalog and custom products to technology licensing, research
 services, large-scale production and life science technical expertise and
 support.
     Under the terms of the agreement, Lifecodes has been granted worldwide
 nonexclusive rights to develop and distribute reagents and Luminex's LabMAP
 instrumentation under its LIFEMATCH(TM) brand.  For these rights, Luminex will
 receive royalties from the commercialization of Lifecodes' products based on
 Luminex's technology.  Lifecodes will focus on developing kits based on the
 multi-analyte profiling capabilities of the Luminex technology.  Lifecodes
 will also market Luminex instrumentation to its customers.
     "We are very excited about our partnership with Luminex and the potential
 of the LabMAP system," stated Robert Linke, Director of Products for
 Lifecodes.  "This technology allows us to develop multiplex HLA DNA assays and
 antibody detection assays for use on a single automated platform.  Previously,
 these two tests were performed with different methodologies and on different
 platforms.  We can now offer the lab a system which can generate savings in
 consumables, labor and time."
     In early May 2001, Lifecodes will make available the first in a series of
 multiplex assays (branded LIFEMATCH(TM)) for HLA DNA typing and antibody
 screening.  Six more assays are planned for release over the next 6 to
 12 months.
     Luminex's LabMAP technology is a proprietary biological testing platform
 that can perform up to 100 assays simultaneously on a single drop of fluid
 with the capability for medium to high throughput assay applications.  This
 system combines the use of low-cost microsphere-based assays with small
 lasers, advanced digital signal processors and proprietary software to offer
 greater speed, precision and flexibility over current bioassay technologies.
     "We are very excited to announce the addition of Lifecodes to our growing
 list of strategic partnerships," stated John Porter, Luminex's Director of
 Business Development.  "Lifecodes is a leading provider of DNA testing
 services and related products for genetic typing of potential donors and
 recipients for transplants, and we are pleased that they are using our
 technology to expand their product lines."
 
     About Lifecodes Corporation
     Lifecodes, headquartered in Stamford, Connecticut, is one of the largest
 providers of molecular products and services for HLA, paternity and forensics.
 The company is a leader in the development, manufacture and distribution of
 molecular HLA typing products used by major bone marrow registries worldwide.
 Lifecodes also owns and operates six testing laboratories, four in the U.S.,
 and one each in Canada and Germany that provide forensic, paternity and HLA
 testing services.  The company offers the most expansive network of identity
 testing labs in North America.  For additional information regarding Lifecodes
 Corp., please contact: Lifecodes Corp. at 550 West Ave., Stamford, CT 06902,
 Phone: 1-800-LIFECODES (543-3263), Fax: 203-328-9599 or Internet:
 www.Lifecodes.com.
 
     About Luminex Corporation
     Luminex Corporation develops, manufactures and markets proprietary
 biological testing technologies with applications throughout the life sciences
 industry.  The company's LabMAP(TM) system is an open-architecture, multi-
 analyte technology platform that delivers fast, accurate and cost-effective
 bioassay results to markets as diverse as pharmaceutical drug discovery,
 clinical diagnostics and biomedical research, including the genomics and
 proteomics research markets.  The company's LabMAP(TM) technology is sold
 worldwide and is already in use in leading research laboratories as well as
 major pharmaceutical, diagnostic and biotechnology companies.  Further
 information on Luminex Corporation or LabMAP(TM) can be obtained on the
 Internet at http://www.luminexcorp.com.
 
     Statements made in this press release that express Luminex's or
 management's intentions, plans, beliefs, expectations or predictions of future
 events are forward-looking statements.  The words "believe," "expect,"
 "intend," "estimate," "anticipate," "will" and similar expressions are
 intended to further identify such forward-looking statements.  It is important
 to note that the company's actual results or performance could differ
 materially from those anticipated or projected in such forward-looking
 statements.  Factors that could cause Luminex's actual results or performance
 to differ materially include risks and uncertainties relating to market demand
 and acceptance of Luminex's products, the company's dependence on strategic
 partners for development and distribution of products, competition, Luminex's
 ability to scale-up manufacturing operations, potential shortages of
 components and the timing of regulatory approvals, as well as the risks
 discussed under the heading "Factors That May Affect Future Results" in
 Luminex's annual report on Form 10-K for the year ended December 31, 2000, as
 filed with the Securities and Exchange Commission.  The forward-looking
 statements contained herein represent the judgment of Luminex as of the date
 of this press release, and Luminex expressly disclaims any intent, obligation
 or undertaking to update or revise such forward-looking statements to reflect
 any change in Luminex's expectations with regard thereto or any change in
 events, conditions or circumstances on which any such statements are based.
 
     Editor's Note:
     Information on Luminex and LabMAP(TM) can be found on the Internet at
 http://www.luminexcorp.com.
     Information on Lifecodes can be found on the Internet at
 http://www.lifecodes.com
 
      Contacts:
      Lifecodes Corporation                   Luminex Corporation
      (203) 328-9533                          (512) 219-8020
      Robert Linke                            John M. Porter
      Director, Products                      Director of Business Development
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X75136655
 
 SOURCE  Luminex Corporation and Lifecodes Corporation